Erasca Inc (ERAS : NASDAQ)
Common Stock
$13.95
USD
-1.61 (-10.32%)
Last updated: 2026-09-23
Follow ERAS
ERAS
Erasca Inc
WealthAwesomePerformance
1 Day
-10.32%
1 Week
-9.21%
1 Month
-20.77%
YTD
-0.25%
Key Statistics
Market Cap
$5.44B
52W High
$24.28
52W Low
$1.79
P/E Ratio
-
50 Day MA
$17.78
200 Day MA
$13.48
Beta
0.65
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/23/2026 | $15.55 | $15.55 | $13.94 | $13.95 | $13.95 | 4,423,431 |
| 9/22/2026 | $15.17 | $15.78 | $15.09 | $15.55 | $15.55 | 4,765,057 |
| 9/21/2026 | $14.96 | $15.29 | $14.60 | $15.04 | $15.04 | 3,737,955 |
| 9/18/2026 | $15.41 | $15.47 | $14.51 | $14.77 | $14.77 | 8,687,400 |
| 9/17/2026 | $15.83 | $16.32 | $14.92 | $15.34 | $15.34 | 7,548,375 |
| 9/16/2026 | $16.31 | $16.64 | $15.19 | $15.36 | $15.36 | 6,086,163 |
| 9/15/2026 | $16.14 | $16.29 | $15.54 | $16.25 | $16.25 | 4,689,700 |
| 9/14/2026 | $16.06 | $16.53 | $15.97 | $16.16 | $16.16 | 2,363,500 |
| 9/11/2026 | $16.05 | $16.54 | $15.87 | $15.88 | $15.88 | 2,883,800 |
| 9/10/2026 | $15.37 | $17.25 | $15.37 | $16.03 | $16.03 | 8,248,100 |
Analyst Price Targets
Based on 8 analysts covering ERAS · as of Sep 17, 2026
Wall Street analysts forecast ERAS stock price to rise 72.9% over the next 12 months.
Consensus
Strong Buy4.63 / 5.00
Avg. Target
US$24.11
+72.9% Upside
Current Price
US$13.95
Last close
Analyst Breakdown (8 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ERAS's historical volatility
30-Day Vol
60.1%
Annualized
90-Day Vol
67.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$11.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$13.14 | US$10.68 – US$16.17 |
| 60 trading days | US$12.38 | US$9.23 – US$16.60 |
| 90 trading days | US$11.66 | US$8.14 – US$16.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-147.74M
- Profit Margin
- 0.00%
- ROE (TTM)
- -78.25%
- EPS (Diluted)
- -0.98
- Book Value
- 1.16
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ERAS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BENF | Beneficient Class A Common Stock | $2.90 | +438.73% |
| JAGX | Jaguar Animal Health Inc | $8.91 | +233.71% |
| WHLR | Wheeler Real Estate Investment Trust, Inc. | $5.44 | +190.91% |
| VSA | TCTM Kids IT Education Inc. | $3.64 | +83.84% |
| ARTL | Artelo Biosciences Inc | $7.31 | +76.14% |
| BFRG | Bullfrog AI Holdings, Inc. Common Stock | $0.95 | +58.33% |
| VTGN | VistaGen Therapeutics Inc | $0.37 | +46.54% |
| IPDN | Professional Diversity Network Inc | $5.42 | +38.97% |
ERAS.US news timeline
1 article covering ERAS.US, most recent first
Latest